Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis by Elsie Grace, Orin Goldblum, Lisa Renda, Noah Agada, Kyoungah See, Craig Leonardi, Alan Menter

Get full text

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis by Bernard Combe, Proton Rahman, Hideto Kameda, Juan D. Cañete, Gaia Gallo, Noah Agada, Wen Xu, Mark C. Genovese

Get full text

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis by Brian G Feagan, Toshifumi Hibi, Vipul Jairath, Nathan Morris, Bruce E Sands, Marla C Dubinsky, Vipin Arora, April N Naegeli, Trevor Lissoos, Mingyang Shan, Jay Tuttle, Noah Agada

Get full text

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure by April Armstrong, Carle Paul, Luis Puig, Wolf Henning Boehncke, Michael Freeman, Hideshi Torii, Kim Papp, Christopher E. M. Griffiths, Andrew Blauvelt, Kristian Reich, Melinda Gooderham, Tadashi Terui, Lisa Renda, Noah Agada, Wen Xu, Gaia Gallo, Mark G. Lebwohl

Get full text